Zealand Pharma 관리

관리 기준 확인 3/4

Zealand Pharma CEO는 Adam Steensberg, Mar2022 에 임명되었습니다 의 임기는 2.67 년입니다. 총 연간 보상은 DKK 24.84M, 23.2% 로 구성됩니다. 23.2% 급여 및 76.8% 보너스(회사 주식 및 옵션 포함). 는 $ 3.25M 가치에 해당하는 회사 주식의 0.048% 직접 소유합니다. 3.25M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 9.6 년입니다.

주요 정보

Adam Steensberg

최고 경영자

DKK 24.8m

총 보상

CEO 급여 비율	23.2%
CEO 임기	2.7yrs
CEO 소유권	0.05%
경영진 평균 재임 기간	3.2yrs
이사회 평균 재임 기간	9.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Adam Steensberg 의 보수는 Zealand Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-DKK 1b
Jun 30 2024	n/a	n/a	-DKK 712m
Mar 31 2024	n/a	n/a	-DKK 739m
Dec 31 2023	DKK 25m	DKK 6m	-DKK 704m
Sep 30 2023	n/a	n/a	-DKK 760m
Jun 30 2023	n/a	n/a	-DKK 986m
Mar 31 2023	n/a	n/a	-DKK 1b
Dec 31 2022	DKK 19m	DKK 4m	-DKK 966m
Sep 30 2022	n/a	n/a	-DKK 855m
Jun 30 2022	n/a	n/a	-DKK 845m
Mar 31 2022	n/a	n/a	-DKK 608m
Dec 31 2021	DKK 10m	DKK 3m	-DKK 755m
Sep 30 2021	n/a	n/a	-DKK 925m
Jun 30 2021	n/a	n/a	-DKK 1b
Mar 31 2021	n/a	n/a	-DKK 909m
Dec 31 2020	DKK 7m	DKK 3m	-DKK 669m
Sep 30 2020	n/a	n/a	-DKK 660m
Jun 30 2020	n/a	n/a	-DKK 545m
Mar 31 2020	n/a	n/a	-DKK 624m
Dec 31 2019	DKK 7m	DKK 3m	-DKK 572m

보상 대 시장: Adam 의 총 보상 ($USD 3.51M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 7.90M ).

보상과 수익: 회사가 수익성이 없는 동안 Adam 의 보상이 증가했습니다.

CEO

Adam Steensberg (50 yo)

2.7yrs

테뉴어

DKK 24,837,000

보상

Mr. Adam Sinding Steensberg, M.D., serves as President and Chief Executive Officer at Zealand Pharma A/S since March 30, 2022. He had been an Executive Vice President of Research & Development and Chief Me...

리더십 팀

이름	위치	테뉴어	보상	소유권
Adam Steensberg	President & CEO	2.7yrs	DKK 24.84m	0.048% $ 3.2m
Henriette Wennicke	EVP & CFO	2yrs	DKK 9.24m	0.0049% $ 327.8k
Ivan Moller	Executive VP & COO	6.7yrs	데이터 없음	0.064% $ 4.3m
David Kendall	Chief Medical Officer and Head of R&D	no data	데이터 없음	0.013% $ 887.6k
Mads Kronborg	Head of Investor Relations & Communication	4.3yrs	데이터 없음	데이터 없음
Ravinder Chahil	EVP & General Counsel	2.8yrs	데이터 없음	0.010% $ 699.5k
Christina Bredal	Executive VP & Chief People Officer	3.6yrs	데이터 없음	0.0095% $ 642.8k
Jens Mikkelsen	Head of Molecular Pharmacology	no data	데이터 없음	데이터 없음
Danilo Verge	Head of Global Medical Affairs	4.2yrs	데이터 없음	데이터 없음
Lykke Romer	VP & Head of Finance and Accounting	no data	데이터 없음	데이터 없음
Eric Cox	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음
Miriam Katz	Assistant Secretary	no data	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: ZLDP.F 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Leonard Kruimer	Independent Director	5.6yrs	DKK 764.00k	0.022% $ 1.5m
Alf Gunnar Nicklasson	Independent Chairman of the Board	9.6yrs	DKK 1.07m	0.026% $ 1.8m
Kirsten Drejer	Independent Vice Chairman	6.6yrs	DKK 583.00k	0.012% $ 840.4k
Ake Lernmark	Member of Advisory Board	13yrs	데이터 없음	데이터 없음
Gudmund Korsgard	Board Observer	no data	데이터 없음	데이터 없음
Jeffrey Berkowitz	Independent Director	5.6yrs	DKK 583.00k	0.012% $ 783.1k
Bernard Charbonnel	Member of Advisory Board	13yrs	데이터 없음	데이터 없음
Richard Pratley	Member of Advisory Board	13yrs	데이터 없음	데이터 없음
Paul Dorian	Member of Advisory Board	13yrs	데이터 없음	데이터 없음
Gert Van Assche	Member of Advisory Board	13yrs	데이터 없음	데이터 없음
Bernadette Connaughton	Independent Director	5.6yrs	DKK 583.00k	0.012% $ 811.4k
Anneline Nansen	Employee Representative Director	3.2yrs	DKK 281.00k	0% $ 0

9.6yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: ZLDP.F 의 이사회는 경험(평균 재직 기간 9.6 년)으로 간주됩니다.

Zealand Pharma 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S Announces Chief Financial Officer Changes

Recent updates

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q2, 2024 Results on Aug 15, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

Zealand Pharma Announces CEO Changes

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

Zealand Pharma A/S Receives First FDA Approval and Prepares for Launch of Zegalogue® (Dasiglucagon) Injection

Zealand Pharma A/S Reaffirms Earnings Guidance for the Full Year of 2021

Zealand Pharma A/S Announces Publication of Phase 3 Trial Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Severe Hypoglycemia in Adult Patients with Diabetes

Zealand Pharma A/S Announces Data from the First Phase 3-Trial with Dasiglucagon in Congenital Hyperinsulinism (Chi)

Zealand Pharma A/S to Report Q3, 2021 Results on Nov 11, 2021

Zealand Pharma Continues to Advance Clinical Programs and Commercial Launch Capabilities

Zealand Pharma A/S (CPSE:ZEAL) completed the acquisition of substantially all assets of Valeritas Holdings, Inc.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령